Major depressive disorder market will reach $5.8 billion by 2025 as awareness and drugs improve

The major depressive disorder (MDD) market, which covers various forms of depression and seasonal affective disorder, is set to rise from $3.2 billion in 2015 to $5.8 billion by 2025, at a compound annual growth rate of 6.1%.

This substantial growth, which will occur across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, the UK, and Japan, will primarily be driven by the growth of atypical antipsychotics, along with the increasing global diagnosed prevalence of MDD, and the potential introduction of six late-stage pipeline products, according to research and consulting firm GlobalData's latest report.

Christos Michaelides, GlobalData’s analyst covering neurology and ophthalmology, explains: “Atypical antipsychotics such as Otsuka/Bristol-Myers Squibb’s [NYSE: BMY] Abilify [aripiprazole], AstraZeneca’s Seroquel XR [quetiapine], and Otsuka/Lundbeck’s Rexulti [(brexpiprazole] are expected to collectively capture approximately 39% of the global market in 2025, and generate an impressive $2.2 billion in sales. Although Abilify and Seroquel will experience some generic erosion over the forecast period, Rexulti will continue to drive sales upwards following its expected launches in the US and Europe in 2018.